RHNanopharma believes the root cause of all modern chronic diseases such as Diabetes, Arthritis, and chronic pain is “ Inflammation”. Focusing on signalling pathways and molecular targets is what we have seen for the drug discovery process. However, for a holistic approach to target systemic inflammaiton, a safe and effective long term anti-inflammatory agent is an unmet need, as serious systemic effects associated with NSAIDs and other biologics limit their daily long term use to combat systemic inflammation.
RH Nanopharma believes that our proprietary formulated safe and effective analgesic/antinflammatory assets (RHN001/RHN002) will address this unmet need to treat acute pain,Post Op pain,chronic arthritis pain in high risk patients ( Elderly, High bleeding risk )in a safe and effective manner. In addition, our nanoformulated Intravenous formulation(RHN002) is an innovative approach to treat acute pain in postoperative patients as well other orphan diseases (undisclosed) related pain syndromes. In addition, Our propietary drug assest is pleiotropic in nature with a solid literature evidence in multiple target diseases as described in below figure.